TITLE: ANALGESIC DOSES OF KETAMINE INTERACT WITH OPIATE RECEPTORS IN VIVO

AUTHORS: C.A. de Sanctis, M.D.; R.L. Bouchal, M.S.; and D.J. Smith, Ph.D.

AFFILIATION: Department of Anesthesiology, West Virginia University Medical Center Morgantown, West Virginia 26506

INTRODUCTION: It has been reported previously that ketamine interacts with opiate receptors in vitro1,2 as an agonist. 3 However, in comparison to the classical opiate drugs like morphine, rather high concentrations (µM) of ketamine are required to produce its effects. Consequently, the present study was done to determine if analgesic doses of ketamine would result in concentrations sufficient to interact with opiate receptors in selected regions of the central nervous system of intact animals. METHODS: An $\frac{1}{3H}$ vivo opiate receptor binding assay using $\frac{3H}{naloxone}$ was performed by a modification of the method of Pert & Snyder4. Briefly, 3H-naloxone (1 µg/kg; 33 µCi/kg) was injected into the tail vein of male, Sprague-Dawley rats and the animals were decapitated 15 min. later (preliminary experiments demonstrated that ³H-naloxone accumulation was maximal 15 min. after injection). When ketamine was administered to compete for radioligand binding, it was administered (i.p.) simultaneously with the ³H-naloxone. (It has been shown ⁵ that the maximal analgesic effect of ketamine, and thus, it is assumed highest concentration of the drug, occurs at 15 min. after i.p. administration). After the animals were sacrificed, the brain (or brain regions) and spinal cord were rapidly dissected on ice and homogenized in 1.0N HCl using a Polytron (setting 6; 20 sec.). The homogenate was centrifuged and aliquots of the super-natant were assayed in duplicate using liquid scintillation spectrophotometry. extraction procedure recovers 90-95% of the 3H-naloxone.

Specific opiate receptor binding (fmoles/ gm tissue) was determined by subtracting the value for the cerebellum (a region devoid of opiate receptors; confirmed in preliminary experiments) from that obtained in other CNS regions. Binding in tissues from ketaminetreated rats was compared to that in salinetreated animals and differences were tested for significance using the Student's t-test. RESULTS: It was observed that ketamine caused a dose-dependent reduction in 3Hnaloxone binding in the brain (minus cerebellum) and spinal cord tissues which was significant at 120 mg/kg of the drug (Table 1). Only doses of the drug (i.p.) that have previously⁵ been shown to produce analgesia (80, 120 & 160 mg/kg) were effective while a dose without analgesic action (40 mg/kg) was ineffective.

The 120 mg/kg dose of ketamine which appeared to produce maximal displacement of H-naloxone was also studied for its effect

in various regions of the rat CNS. The drug caused a reduction in all areas studied but the reduction was significant in only those regions denoted with an asterisk in Table 2.0 DISCUSSION: These results demonstrate that the concentration of ketamine achieved in the rat CNS after administration of analgesic doses of the drug effectively interacts with opiate receptors. Since it has been shown

| | action of the drug may be partia |
|---|--|
| nediated- | through opiate-activated neurona |
| processes | deprivate mode but a position with cerelinal. |
| | Votering (/kg) |
| | Ketamine (mg/kg) |
| 0 | 620,52 635,20 556,40 562,20 612,74 |
| Cerebellum | 672106 703191 530176 650171 \$ 5291106 |
| Brain+ | 0/3+90 /03+61 330+/4 439+/1" 320+104 |
| Spinal Cor | 14 300470 294444 244440 172430" 101439" |
| + values are binding. * 0.05. N > | fmoles 3H haloxone/gm tissue + 5.E. re minus cerebellum and represent specification of the first from control, P g/group. |
| + values are + values a binding. * 0.05, N > | fmoles 3H haloxone/gm tissue ± 5.E. re minus cerebellum and represent specification of the first from control, P B/group. TABLE 2 Ketamine (120 mg/kg) Saline |
| + values abinding. * 0.05. N > | fmoles 3H haloxone/gm tissue ± 5.E. re minus cerebellum and represent specification of the first from control, P 3/group. TABLE 2 Ketamine (120 mg/kg) Saline 593+23 638+17 |
| + values are + values a binding. * 0.05, N > Cerebellum | fmoles 3H haloxone/gm tissue ± 5.E. re minus cerebellum and represent specification of the first from control, P 3/group. TABLE 2 Ketamine (120 mg/kg) Saline 593+23 638+17 367+44 495+59 |
| + values are + values a binding. * 0.05, N > Cerehellum Medulla Hippocampu | fmoles 3H haloxone/gm tissue ± 5.E. re minus cerebellum and represent specifications of the first from control, P O/group. TABLE 2 Ketamine (120 mg/kg) Saline 593+23 367+44 495+59 5* 571+93 810+99 |
| values are + values a binding. * 0.05. N > Cerebellum Medulla Hippocampu Midbrain | fmoles 3H haloxone/gm tissue ± 5.E. re minus cerebellum and represent specificantly different from control, P B/group. TABLE 2 Ketamine (120 mg/kg) Saline 593+23 367+44 495+59 5* 571+93 1013+126 1103+64 |
| + values abinding. * 0.05. N > Cerebellum Medulla Hippocampu Midbrain Thalamus* | fmoles 3H haloxone/gm tissue + 5.E. re minus cerebellum and represent specificantly different from control, P 9/group. TABLE 2 Ketamine (120 mg/kg) Saline 593+23 367+44 495+59 571+93 1013+126 1040+104 1270+38 |
| + values are + values a binding. * 0.05. N > Cerehellum Medulla Hippocampu Midbrain Thalamus* Hypothalam | fmoles 3H haloxone/gm tissue + 5.E. re minus cerebellum and represent specificantly different from control, P 7/group. TABLE 2 Ketamine (120 mg/kg) Saline 593+23 367+44 495+59 571+93 1013+126 1040+104 1270+38 1062+320 |
| values are + values a binding. * 0.05. N > Cerehellum Medulla Hippocampu Midbrain Thalamus* Hypothalam Striatum* | fmoles 3H haloxone/gm tissue + 5.E. re minus cerebellum and represent specificantly different from control, P 3/group. TABLE 2 Ketamine (120 mg/kg) Saline 593+23 367+44 495+59 5* 571+93 810+99 1013+126 1040+104 1270+38 18 877+215 703+186 1031+24 |
| ratues are + values a binding. * 0.05. N > Cerehellum Medulla Hippocampu Midbrain Thalamus* Hypothalam Striatum* Cortex* | in vitro, 3 it seems likely that action of the drug may be partially through opiate-activated neuronal through opiate-activated neuronal Retamine (mg/kg) Saline 40 80 120 160 628+52 635+30 556+40 562+39 613+74 673+96 703+81 530+74 459+71* 528+104 1+ 308+70 294+44 244+48 172+38* 181+39* fmoles 3H naloxone/gm tissue + S.E. re minus cerebellum and represent specifically different from control, Particle 120 mg/kg) TABLE 2 Ketamine (120 mg/kg) Saline 593+23 638+17 367+44 495+59 571+93 810+99 1013+126 103+64 1040+104 1270+38 108 877+215 1062+320 703+186 1031+24 620+55 1004+60 104 298+21 441+69 expressed as in Table 1 and, with the except cerebellum value, represent specific being ficantly reduced by ketamine P < 0.05. |

REFERENCE:

- 1) Smith, D.J., Pekoe, G.M., Martin, L.L. & Coalgate B.: The interaction of ketamine with the opiate receptor. Life Sci. 26:789-795, 1980.
- 2) Finck, A.D., & Ngai, S.H.: A possible mechanism of ketamine-induced analgesia. Anesthesiology 53: S34, 1979.
- 3) Smith, D.J., Westfall, D.P., & Adams, J.D.: Ketamine interacts with opiate receptors as an agonist.
- Anesthesiology 53:85, 1980. 4) Pert, C.B. & Snyder, S.H.: Identification of opiate receptor binding in intact animals. Life Sci. 16:1623-1634, 1975.
- 5) Pekoe, G.M. & Smith, D.J.: The involvement of opiate and monoaminergic neuronal systems in the analgesic effects of ketamine. Pain 12:57-73, 1982.